insights_auto
Why is GNLX up 2.40%?
Dive Deeperchevron_right
GNLX:NASDAQ
Genelux Corp
$2.56
arrow_upward
+2.40%(+0.060) 1D
Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.48
High
$2.57
Low
$2.47
Mkt. cap
115.83M
Avg. vol.
275.44K
Volume
154.65K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
Open
$2.48
High
$2.57
Low
$2.47
Mkt. cap
115.83M
Avg. vol.
275.44K
Volume
154.65K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
News stories
From web sources and news partners
FXLeaders
·
2 hours ago
Dow Jones and Nasdaq Futures Start Higher Ahead of US Inflation Data
CryptoRank
·
10 hours ago
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Hindustan Times
·
6 hours ago
Why are 54% of US stocks down 20% as the S&P 500 nears a record high? | Hindustan Times
Traders Union
·
4 hours ago
Yuriy Matso: S&P500 negative beta to SPY at record 18.9 percent
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com